Supreme Court criticises hospitals and government over exorbitant mark-ups on cancer drugs

KanoonHQ Legal Gazette · AI-generated brief from the source linked below. How briefs are made

Published 27 October 2026

Case: Not specified in source
Court: Supreme Court of India
Bench: Justices B.R. Gavai and Sandeep Mehta
Source: Bar & Bench

Bottom Line Up Front (BLUF)

The Supreme Court, comprising Justices B.R. Gavai and Sandeep Mehta, criticised hospitals and the government for mark-ups of up to 1,000% on cancer drugs. The Court questioned the justification for such high prices, particularly for essential medicines, and directed the government to address the issue.

Ratio Decidendi · Legal Principle Established

The court's observations indicate a principle that essential medicines, particularly for life-threatening diseases like cancer, should not be subject to exorbitant mark-ups, and that both healthcare providers and the government have a responsibility to ensure affordability and accessibility.

Practice & Procedural Impact for Advocates

Advocates may use this observation to argue for price regulation or challenge excessive billing for cancer treatments. Litigants may find grounds to seek redress for inflated drug costs, potentially leading to public interest litigation.

Key Legal Takeaways

1Supreme Court expressed concern over 1,000% mark-ups on cancer drugs.
2The Court questioned the government's inaction on drug pricing.
3The issue highlights the need for greater regulation in pharmaceutical pricing.

The Legal Issue The Supreme Court, while hearing a matter, raised serious concerns regarding the exorbitant mark-ups on cancer drugs by hospitals and the perceived inaction of the government in regulating these prices. The bench specifically questioned the justification for mark-ups reaching up to 1,000% on essential medicines, asking, "Can you justify this loot?"

Court's Reasoning Justices B.R. Gavai and Sandeep Mehta expressed their dismay at the significant disparity between the procurement cost of cancer drugs and their final selling price to patients. The Court highlighted that such practices make life-saving treatments unaffordable for many, thereby impacting the fundamental right to health. The bench indicated that both hospitals and the government bear responsibility for ensuring that essential medicines are accessible and reasonably priced, rather than being subject to exploitative pricing strategies.

What Follows The Supreme Court has directed the Union Government to address the issue of high mark-ups on cancer drugs. This observation is likely to prompt the government to review existing drug pricing policies and potentially introduce new regulations to control the prices of essential medicines. The Court's strong remarks underscore the need for immediate action to ensure affordability and prevent profiteering in the healthcare sector.